Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 12, 2015-12 ,pp. : 1266-1273

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use and Spending for Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 9, 2015-09 ,pp. : 1210-1218

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease‐modifying anti‐rheumatic drugs in patients with rheumatoid arthritis: correlation with clinical and laboratory parameters

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 18, Iss. 4, 2015-05 ,pp. : 421-432

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis

By Hochberg Marc C.   Berry Scott   Broglio Kristine   Rosenblatt Lisa   Nadkarni Anagha   Trivedi Digisha   Hebden Tony  

Current Medical Research and Opinion, Vol. 29, Iss. 10, 2013-10 ,pp. : 1213-1222

Informa Healthcare

Access to resources Recommend Favorite

Utility of ultrasonography in guiding modification of disease modifying anti‐rheumatic drugs and steroid therapy for inflammatory arthritis in routine clinical practice

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 21, Iss. 1, 2018-01 ,pp. : 155-160

John Wiley & Sons Inc

Access to resources Recommend Favorite